APLIDINE TREATMENT OF CANCERS

摘要

Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumours, and various dosing regimes are given. Tumor reduction has been observed in several tumour types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumour activity.